CA3042731A1 - Inhibitors of interleukin-1 receptor-associated kinases and uses thereof - Google Patents
Inhibitors of interleukin-1 receptor-associated kinases and uses thereof Download PDFInfo
- Publication number
- CA3042731A1 CA3042731A1 CA3042731A CA3042731A CA3042731A1 CA 3042731 A1 CA3042731 A1 CA 3042731A1 CA 3042731 A CA3042731 A CA 3042731A CA 3042731 A CA3042731 A CA 3042731A CA 3042731 A1 CA3042731 A1 CA 3042731A1
- Authority
- CA
- Canada
- Prior art keywords
- optionally substituted
- certain embodiments
- compound
- unsubstituted
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662425503P | 2016-11-22 | 2016-11-22 | |
| US62/425,503 | 2016-11-22 | ||
| PCT/US2017/063139 WO2018098367A1 (en) | 2016-11-22 | 2017-11-22 | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3042731A1 true CA3042731A1 (en) | 2018-05-31 |
Family
ID=60703094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3042731A Pending CA3042731A1 (en) | 2016-11-22 | 2017-11-22 | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10975055B2 (OSRAM) |
| EP (1) | EP3544970B1 (OSRAM) |
| JP (1) | JP7308146B2 (OSRAM) |
| AU (1) | AU2017363313B2 (OSRAM) |
| CA (1) | CA3042731A1 (OSRAM) |
| WO (1) | WO2018098367A1 (OSRAM) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| IL322809A (en) | 2017-09-22 | 2025-10-01 | Kymera Therapeutics Inc | Protein Decomposers and Their Uses |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| EP3817822A4 (en) | 2018-07-06 | 2022-07-27 | Kymera Therapeutics, Inc. | PROTEIN DEGRADANTS AND USES THEREOF |
| WO2020081572A1 (en) * | 2018-10-15 | 2020-04-23 | Dana-Farber Cancer Institute, Inc. | Transcriptional enhanced associate domain (tead) transcription factor inhibitors and uses thereof |
| CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CN113939300A (zh) | 2019-04-05 | 2022-01-14 | 凯麦拉医疗公司 | Stat降解剂和其用途 |
| AU2020386639A1 (en) * | 2019-11-22 | 2022-06-02 | Shangpharma Innovation Inc. | Caspase 6 inhibitors and uses thereof |
| JP7390487B2 (ja) * | 2019-12-03 | 2023-12-01 | サムジン ファーマシューティカル カンパニー，リミテッド | 焦点接着キナーゼ阻害剤としての新規なアダマンタン誘導体 |
| US11591332B2 (en) | 2019-12-17 | 2023-02-28 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| JP2023509366A (ja) | 2019-12-17 | 2023-03-08 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| US11679109B2 (en) | 2019-12-23 | 2023-06-20 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| PH12022552458A1 (en) | 2020-03-19 | 2024-01-22 | Kymera Therapeutics Inc | Mdm2 degraders and uses thereof |
| CN115484954A (zh) * | 2020-03-23 | 2022-12-16 | 达纳-法伯癌症研究所股份有限公司 | Irak1的有效和选择性不可逆抑制剂 |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| US20230295146A1 (en) * | 2020-07-24 | 2023-09-21 | The University Of Rochester | Inhibitors of interleukin-1 receptor-associated kinases 1 and 4 |
| MX2023007852A (es) | 2020-12-30 | 2023-07-07 | Kymera Therapeutics Inc | Degradadores de cinasas asociadas al receptor de interleucina-1 (irak) y usos de los mismos. |
| EP4291187A4 (en) | 2021-02-15 | 2025-01-15 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| EP4308096A4 (en) * | 2021-03-17 | 2025-04-16 | Merck Sharp & Dohme LLC | Heteroaroylamides as LRRK2 inhibitors, pharmaceutical compositions and uses thereof |
| CN117715904A (zh) | 2021-05-07 | 2024-03-15 | 凯麦拉医疗公司 | Cdk2降解剂和其用途 |
| EP4422635A4 (en) | 2021-10-29 | 2025-11-26 | Kymera Therapeutics Inc | IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS |
| AU2023214044A1 (en) | 2022-01-31 | 2024-08-08 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI491606B (zh) * | 2009-07-13 | 2015-07-11 | Gilead Sciences Inc | 調節細胞凋亡信號之激酶的抑制劑 |
| JP6106685B2 (ja) | 2011-11-17 | 2017-04-05 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤 |
| EP2903613B1 (en) | 2012-10-08 | 2017-11-22 | Merck Sharp & Dohme Corp. | Pyrazole derivatives useful as inhibitors of irak4 activity |
| EP3079682A4 (en) * | 2013-12-13 | 2017-08-30 | Dana-Farber Cancer Institute, Inc. | Methods to treat lymphoplasmacytic lymphoma |
| ES2728403T3 (es) * | 2014-01-09 | 2019-10-24 | Merck Patent Gmbh | Derivados de pirimidin pirazolilo y su uso como inhibidores de IRAK |
| WO2015154038A1 (en) * | 2014-04-04 | 2015-10-08 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| SG11201702741SA (en) | 2014-11-20 | 2017-04-27 | Merck Patent Gmbh | Heteroaryl compounds as irak inhibitors and uses thereof |
-
2017
- 2017-11-22 JP JP2019527449A patent/JP7308146B2/ja active Active
- 2017-11-22 EP EP17817469.4A patent/EP3544970B1/en active Active
- 2017-11-22 WO PCT/US2017/063139 patent/WO2018098367A1/en not_active Ceased
- 2017-11-22 US US16/462,200 patent/US10975055B2/en active Active
- 2017-11-22 CA CA3042731A patent/CA3042731A1/en active Pending
- 2017-11-22 AU AU2017363313A patent/AU2017363313B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20190276426A1 (en) | 2019-09-12 |
| WO2018098367A1 (en) | 2018-05-31 |
| JP2019535759A (ja) | 2019-12-12 |
| US10975055B2 (en) | 2021-04-13 |
| EP3544970B1 (en) | 2021-11-17 |
| AU2017363313B2 (en) | 2021-06-24 |
| US20200299257A9 (en) | 2020-09-24 |
| JP7308146B2 (ja) | 2023-07-13 |
| EP3544970A1 (en) | 2019-10-02 |
| AU2017363313A1 (en) | 2019-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017363313B2 (en) | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof | |
| AU2017363307B2 (en) | Inhibitors of cyclin-dependent kinase 12 (CDK12) and uses thereof | |
| JP2021514958A (ja) | 選択的なタンパク質分解を誘導するための低分子およびその使用法 | |
| EP3876939A1 (en) | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof | |
| JP7675070B2 (ja) | 治療、特にｍｙｄ８８変異疾患における使用のためのｈｃｋ阻害剤としてのピラゾロピリミジン誘導体 | |
| CA3132387A1 (en) | Degraders of cyclin-dependent kinase 12 (cdk12) and uses thereof | |
| WO2017040304A1 (en) | Malt1 inhibitors and uses thereof | |
| EP3876930A1 (en) | Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof | |
| WO2020263935A1 (en) | Hck degraders and uses thereof | |
| CA2990477A1 (en) | Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases | |
| CA3217380A1 (en) | Nampt inhibitors and uses thereof | |
| CA3106548A1 (en) | Histone demethylase 5 inhibitors and uses thereof | |
| AU2021284369A1 (en) | Quinazoline-derived HCK inhibitors for use in the treatment of MYD88 mutated diseases | |
| AU2020301399B2 (en) | HCK degraders and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220924 |
|
| EEER | Examination request |
Effective date: 20220924 |
|
| EEER | Examination request |
Effective date: 20220924 |
|
| EEER | Examination request |
Effective date: 20220924 |
|
| EEER | Examination request |
Effective date: 20220924 |